International Commissary Corporation Issues Voluntary Recall of Marie Callender’s Cheese Biscuit Mix Due To Possible Health Risk

International Commissary Corporation (ICC) has issued a voluntary recall of certain lots of two retail products: Marie Callender’s 7oz & 14oz Cheese Biscuit Mix. The 7 oz recalled product has Best By dates of 3/22/17 and 5/17/17 and was sold in retail stores in the following states – AL, CA, WA, UT, and TX. The 14 oz recalled product has a Best Buy date of 6/17/17 and was sold only in Stockton, CA.

Kerry Inc. Recalls Golden Dipt® Jalapeño Breaders Because of Possible Health Risk

Kerry Inc. of Beloit, WI is recalling two lots of Golden Dipt Jalapeno Breader that were sold to foodservice distributors because one of our suppliers recalled an ingredient used in our mix for the potential presence of E. coli O121. Kerry Inc. was notified by our supplier that two of their products, a red bell pepper nugget and a jalapeno nugget, were made with a small percentage of affected flour which was recalled by General Mills because it may be contaminated with E. coli O121.
Read The Complete Story!

IKEA N.A. Services, LLC Voluntarily Issues Expanded Recall and Allergy Alert on Undeclared Milk, Almond, and/or Hazelnut on Certain IKEA Chocolate Products

CHOKLAND MORK, CHOKLAND MORK 70%, CHOKLAD LINGON & BLABAR, CHOKLAD NOT, GODIS CHOKLADKROKANT, GODIS CHOKLADRAN and CHOKLAD LJUS, are being recalled due to undeclared Milk, Hazelnuts and/or Almond. “All Best Before Dates,” Sold from April 30, 2015 to July 1, 2016.
Read The Complete Story!

Alere to Initiate Voluntary Withdrawal of the Alere INRatio and INRatio2 PT/INR Monitor System

WALTHAM, Mass. – Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc. (NYSE:ALR) will be initiating a voluntary withdrawal of the Alere INRatio and INRatio2 PT/INR Monitoring System. Alere is working with the FDA to determine the most appropriate timing for product discontinuation and will provide guidance on transitioning patients to an alternate solution to allow them to continue anti-coagulation monitoring in the least disruptive manner possible.

FDA approves new medication for dry eye disease

The U.S. Food and Drug Administration approved Xiidra (lifitegrast ophthalmic solution) for the treatment of signs and symptoms of dry eye disease, on Monday, July 11, 2016. Xiidra is the first medication in a new class of drugs, called lymphocyte function-associated antigen 1 (LFA-1) agonist, approved by the FDA for dry eye disease.

FDA approves first MRI-guided focused ultrasound device to treat essential tremor

The U.S. Food and Drug Administration today approved the first focused ultrasound device to treat essential tremor in patients who have not responded to medication. ExAblate Neuro uses magnetic resonance (MR) images taken during the procedure to deliver focused ultrasound to destroy brain tissue in a tiny area thought to be responsible for causing tremors.